Anhui Poly Pharm. Co., Ltd. (hereinafter referred to as “Anhui Poly”), a holding subsidiary of Hainan Poly Pharm. Co., Ltd. (hereinafter referred to as “Poly Pharm.”), has recently received written confirmation for active substance exported to EU (hereinafter referred to as “WC”) of gadobutrol API and certificate of a pharmaceutical product (hereinafter referred to as “COPP”) of cyclophosphamide API issued by Anhui NMPA.
From Milan to the ancient capital Xi'an, after participating in the 35th CPHI Milan 2024 (World Pharmaceutical API Exhibition) held at the Milan Exhibition Center in Italy, Poly witnessed the grand opening of the 91st CPHI/Intermediates/Packaging/Equipment Fair from October 16-18, 2024.
Anhui Poly Pharm. Co., Ltd. (hereinafter referred to as “Anhui Poly”), a holding subsidiary of Hainan Poly Pharm. Co., Ltd. (hereinafter referred to as “Poly Pharm.”), has recently received Notice of Approval for Listing Application of Gadoteridol API issued by National Medical Products Administration (hereinafter referred to as “NMPA”).
Anhui Poly Pharm. Co., Ltd. (hereinafter referred to as “Anhui Poly”), a holding subsidiary of Hainan Poly Pharm. Co., Ltd. (hereinafter referred to as “Poly Pharm.”), has recently received Notice of Approval for Listing Application of Memantine Hydrochloride API issued by National Medical Products Administration (hereinafter referred to as “NMPA”).
On October 8-10, 2024, the 35th CPhi Milan 2024 (World Pharmaceutical Raw Materials Exhibition) was grandly opened at the Milan Exhibition Center, Italy.From Haikou Hainan to Milan, Italy, Poly has brought expert teams and business backbone to participate in the event. Poly has fully demonstrated its strong comprehensive strength and international strategic layout through numerous dimensions such as rich scientific and technological innovation research and development results, strict quality assurance system and firm international registration advantages, which has attracted many customers for in-depth exchanges and cooperation.
